Meeting
2011 ASCO Annual Meeting
Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC).
Authors
B. H. Grønberg
Norwegian University of Science and Technology and St. Olav's Hospital, Trondheim, Norway
B. H. Grønberg , M. Lund-Iversen , E. H. Strøm , O. T. Brustugun , H. Scott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Metastatic/Non-small Cell
Track
Lung Cancer
Sub Track
Metastatic
Citation
J Clin Oncol 29: 2011 (suppl; abstr 7535)
Abstract #
7535
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2014 Genitourinary Cancers Symposium
Molecular profiling of advanced refractory prostate cancer.
First Author: Rebecca A. Feldman
Poster
2013 ASCO Annual Meeting
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.
First Author: Yi Long Wu
Poster
2012 ASCO Annual Meeting
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
First Author: Caicun Zhou